C:\Program Files\Stnexp\Queries\10502291 (amd).str





```
chain nodes :
    25  26  27  28  29  31
ring nodes :
    1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24
chain bonds :
    3-31  5-25  10-25  12-26  15-27  18-29  20-29  26-27  27-28
ring bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-18  14-15  15-16
    16-17  17-18  19-20  19-24  20-21  21-22  22-23  23-24
exact/norm bonds :
    3-31  5-25  10-25  12-26  19-20  19-24  20-21  21-22  22-23  23-24  26-27  27-28
exact bonds :
    15-27  18-29  20-29
normalized bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  13-14  13-18  14-15  15-16
    16-17  17-18
isolated ring systems :
    containing 1 : 7 : 13 : 19 :


Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom  11:Atom
    12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom  21:Atom
    22:Atom  23:Atom  24:Atom  25:CLASS  26:CLASS  27:CLASS  28:CLASS  29:CLASS  31:Atom
Generic attributes :
    31:
    Saturation               : Unsaturated
    Number of Carbon Atoms : less than 7
    Number of Hetero Atoms : Exactly 1
    Type of Ring System    : Monocyclic

Element Count :
    Node 31: Limited
        C,C5
        N,N1
```

O,OO
S,SO

=>
Uploading C:\Program Files\Stnexp\Queries\10502291 (amd).str



chain nodes :
25 26 27 28 29 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24
chain bonds :
5-25 10-25 12-26 15-27 18-29 20-29 26-27 27-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18 19-20 19-24 20-21 21-22 22-23 23-24
exact/norm bonds :
5-25 10-25 12-26 19-20 19-24 20-21 21-22 22-23 23-24 26-27 27-28
exact bonds :
15-27 18-29 20-29
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 : 19 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 31:Atom 32:Atom
Generic attributes :

```
31:
Saturation             : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System    : Monocyclic

Element Count :
Node 31: Limited
    C,C5
    N,N1
    O,O0
    S,S0




L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 21:06:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      188 TO ITERATE

100.0% PROCESSED      188 ITERATIONS                                 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2938 TO     4582
PROJECTED ANSWERS:               8 TO      329

L2            8 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 21:08:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4323 TO ITERATE

100.0% PROCESSED     4323 ITERATIONS                               184 ANSWERS
SEARCH TIME: 00.00.01

L3          184 SEA SSS FUL L1

=> => s l3
L4        3644 L3

=>
=> =>
```

Uploading C:\Program Files\Stnexp\Queries\10502291 (sub 1).str





chain nodes :
7
ring nodes :
1 2 3 4 5 6
chain bonds :
1-7
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR

Structure attributes must be viewed using STN Express query preparation.

=> s l5 sub=l3 sss sam

```
SAMPLE SUBSET SEARCH INITIATED 21:24:32 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -        0 TO ITERATE

100.0% PROCESSED        0 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):           ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):          0 TO        0
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):             0 TO        0

L6            0 SEA SUB=L3 SSS SAM L5

=>
Uploading C:\Program Files\Stnexp\Queries\10502291 (sub 2).str
```





```
chain nodes :
7
ring nodes :
1  2  3  4  5  6
chain bonds :
2-7
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
1-2  1-6  2-3  2-7  3-4  4-5  5-6
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS



L7      STRUCTURE UPLOADED

=> d l7
L7 HAS NO ANSWERS
L7              STR
```



Structure attributes must be viewed using STN Express query preparation.

=> s l7 sub=l3 sss sam
SAMPLE SUBSET SEARCH INITIATED 21:26:22 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 0 TO 0
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 0 TO 0

L8 0 SEA SUB=L3 SSS SAM L7

=> s l7 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 21:26:30 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L9 4 SEA SUB=L3 SSS FUL L7

=> s l5 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 21:26:50 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

L10 4 SEA SUB=L3 SSS FUL L5

=> s l9 or l10
L11 8 L9 OR L10

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 86.96 279.39

FILE 'CAPLUS' ENTERED AT 21:27:11 ON 04 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Aug 2008 VOL 149 ISS 6
FILE LAST UPDATED: 3 Aug 2008 (20080803/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l11
L12 5 L11

=> d l12 1-5 bib,ab,hitstr

L12 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:404120 CAPLUS
DN 148:575723
TI In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1
AU Rochat, Bertrand; Zoete, Vincent; Grosdidier, Aurelien; von Grunigen, Sandrine; Marull, Marc; Michielin, Olivier
CS Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, 1011, Switz.
SO Biopharmaceutics & Drug Disposition (2008), 29(2), 103-118
CODEN: BDDID8; ISSN: 0142-2782
PB John Wiley & Sons Ltd.
DT Journal
LA English
AB The main objective of the study was to examine the biotransformation of the anticancer drug imatinib in target cells by incubating it with oxidoreductases expressed in tumor cells. The second objective was to obtain an in silico prediction of the potential activity of imatinib metabolites. An in vitro enzyme kinetic study was performed with cDNA expressed human oxidoreductases and LC-MS/MS anal. The kinetic parameters (Km and Vmax) were determined for six metabolites. A mol. modeling approach was used to dock these metabolites to the target Abl or Bcr-Abl kinases. CYP3A4 isoenzyme showed the broadest metabolic capacity, whereas CYP1A1, CYP1B1 and FMO3 isoenzymes biotransformed imatinib with a high intrinsic clearance. The predicted binding modes for the metabolites to Abl were comparable to that of the parent drug, suggesting potential activity. These findings indicate that CYP1A1 and CYP1B1, which are known to be overexpressed in a wide range of tumors, are involved in the biotransformation of imatinib. They could play a role in imatinib disposition in the targeted stem, progenitor and differentiated cancer cells, with a possible contribution of the metabolites toward the activity of the drug.
IT 571186-91-9 571186-92-0
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(in vitro biotransformation of imatinib by tumor expressed CYP1A1 and CYP1B1)
RN 571186-91-9 CAPLUS
CN Benzamide, 4-[(4-methyl-4-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 571186-92-0 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RE.CNT 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:345353 CAPLUS
DN 147:39589
TI Identification of imatinib mesylate degradation products obtained under stress conditions
AU Szczepek, W. J.; Kosmacinska, B.; Bielejewska, A.; Luniewski, W.; Skarzynski, M.; Rozmarynowska, D.
CS Pharmaceutical Research Institute, Warsaw, 01-793, Pol.
SO Journal of Pharmaceutical and Biomedical Analysis (2007), 43(5), 1682-1691
CODEN: JPBADA; ISSN: 0731-7085
PB Elsevier B.V.
DT Journal
LA English
AB In this paper, the decomposition of imatinib mesylate (ImM) under hydrolytic (neutral, acidic, alkaline), oxidative and photolytic conditions was studied. The imatinib mesylate is practically photostable and stable under neutral conditions. The main degradation products under acidic and alkaline conditions are compds.: 4-methyl-N 3-(4-pyridin-3-yl-pyrimidyn-2-yl)-benzene-1,3-diamine and 4-(4-methyl-piperazin-1-ylmethyl)-benzoic acid. The main degradation products under oxidation conditions, i.e. 4-[(4-methyl-4-oxido-piperazin-1-yl)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide, 4-[(4-methyl-1-oxido-piperazin-1-yl)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide and 4-[(4-methyl-1,4-dioxido-piperazin-1-yl)-methyl]-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide, were isolated from the reaction mixts. and identified by the HPLC, 1H NMR and MS techniques. During stress study the suitability of the proposed HPLC method to control purity of the samples was verified.
IT 571186-91-9 571186-93-1 938082-57-6
RL: OCU (Occurrence, unclassified); PEP (Physical, engineering or chemical process); OCCU (Occurrence); PROC (Process)
(imatinib mesylate degradation products identification obtained under stress conditions)
RN 571186-91-9 CAPLUS
CN Benzamide, 4-[(4-methyl-4-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 571186-93-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1,4-dioxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 938082-57-6 CAPLUS
CN Benzamide, 4-[(4-methyl-1-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:1337398 CAPLUS
DN 146:81891
TI Process for preparation of isotopically labeled imatinib and intermediates
IN Salter, Rhys; Rodriguez Perez, Maria Ines; Moenius, Thomas; Voges, Rolf; Andres, Hendrik; Bordeaux, Kirk
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 36pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006133904	A2	20061221	WO 2006-EP5676	20060613
	WO 2006133904	A3	20070322		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006257316	A1	20061221	AU 2006-257316	20060613
	CA 2610193	A1	20061221	CA 2006-2610193	20060613
	EP 1896447	A2	20080312	EP 2006-754340	20060613
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	IN 2007DN09474	A	20080627	IN 2007-DN9474	20071207
	CN 101198601	A	20080611	CN 2006-80020947	20071212
	MX 200715876	A	20080304	MX 2007-15876	20071213
	KR 2008042066	A	20080514	KR 2008-700866	20080111
PRAI	GB 2005-12091	A	20050614		
	WO 2006-EP5676	W	20060613		

OS MARPAT 146:81891
AB This invention relates to a new process for preparation of isotopically labeled imatinib and intermediates. For example, 4-chloromethyl-N-[4-methyl-3-[4-(1-oxido-3-pyridinyl)-[2-14C]-pyrimidin-2-ylamino]phenyl]benzamide hydrochloride (preparation given) was reacted with 1-methylpiperazine in ethanol, followed by the addition of methanesulfonic acid to give methanesulfonate of I [X = 14C]. Isotopically labeled intermediates were also described.
IT 917358-55-5P 917358-56-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of isotopically labeled imatinib and intermediates)
RN 917358-55-5 CAPLUS
CN Benzamide, 4-[(4-methyl-4-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl-2-14C]amino]phenyl]- (CA INDEX NAME)



RN 917358-56-6 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl-2-14C]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)



L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:1068885 CAPLUS
DN 143:338914
TI Metabolism and disposition of imatinib mesylate in healthy volunteers
AU Gschwind, Hans-Peter; Pfaar, Ulrike; Waldmeier, Felix; Zollinger, Markus; Sayer, Claudia; Zbinden, Peter; Hayes, Michael; Pokorny, Rolf; Seiberling, Michael; Ben-Am, Monique; Peng, Bin; Gross, Gerhard
CS Exploratory Development/Drug Metabolism & Pharmacokinetics, Novartis Pharma AG, Basel, Switz.
SO Drug Metabolism and Disposition (2005), 33(10), 1503-1512
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
AB Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of 14C-labeled imatinib mesylate. Biol. fluids were analyzed for total radioactivity, imatinib, and its main metabolite CGP74588. Metabolite patterns were determined by radio-high-performance liquid chromatog. with off-line microplate solid scintillation counting and characterized by liquid chromatog.-mass spectrometry. Imatinib treatment was well tolerated without serious adverse events. Absorption was rapid (tmax 1-2 h) and complete with imatinib as the major radioactive compound in plasma. Maximum plasma concns. were 0.921±0.095 μg/mL (mean ± S.D., n = 4) for imatinib and 0.115±0.026 μg/mL for the pharmacol. active N-desmethyl metabolite (CGP74588). Mean plasma terminal elimination half-lives were 13.5±0.9 h for imatinib, 20.6±1.7 h for CGP74588, and 57.3±12.5 h for 14C radioactivity. Imatinib was predominantly cleared through oxidative metabolism Approx. 65 and 9% of total systemic exposure [AUC0-24 h (area under the concentration time curve) of radioactivity] corresponded to imatinib and CGP74588, resp. The remaining proportion corresponded mainly to oxidized derivs. of imatinib and CGP74588. Imatinib and its metabolites were excreted predominantly via the biliary-fecal route. Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine). Approx. 28 and 13% of the dose in the excreta corresponded to imatinib and CGP74588, resp.
IT 571186-91-9, CGP 71422 571186-92-0, CGP 72383
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolism and disposition of imatinib mesylate in healthy volunteers)
RN 571186-91-9 CAPLUS
CN Benzamide, 4-[(4-methyl-4-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

RN 571186-92-0 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:591164 CAPLUS
DN 139:149642
TI Preparation of benzoylaminophenylaminopyrimidinylpyridines as antitumor agents
IN Boernsen, Klaus Olaf; End, Peter; Gross, Gerhard; Pfaar, Ulrike
PA Novartis Ag, Switz.; Novartis Pharma Gmbh
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062220	A1	20030731	WO 2003-EP613	20030122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2474104	A1	20030731	CA 2003-2474104	20030122
	EP 1470120	A1	20041027	EP 2003-731700	20030122
	EP 1470120	B1	20071212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007058	A	20041228	BR 2003-7058	20030122
	JP 2005519908	T	20050707	JP 2003-562099	20030122
	CN 1646519	A	20050727	CN 2003-802708	20030122
	EP 1783126	A2	20070509	EP 2007-101787	20030122
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR, RO				
	AT 380807	T	20071215	AT 2003-731700	20030122
	ES 2294293	T3	20080401	ES 2003-731700	20030122
	IN 2004CN01599	A	20060224	IN 2004-CN1599	20040720
	KR 778163	B1	20071128	KR 2004-711382	20040722
	MX 2004PA07130	A	20041029	MX 2004-PA7130	20040723
	US 20050209452	A1	20050922	US 2005-502291	20050429
	KR 2007058019	A	20070607	KR 2007-711065	20070515
PRAI	GB 2002-1508	A	20020123		
	EP 2003-731700	A3	20030122		
	WO 2003-EP613	W	20030122		
	KR 2004-711382	A3	20040722		

OS MARPAT 139:149642
AB Title compds. I [R1 = , OH; R2 = H, alkyl, hydroxyalkyl; A = NR3R4, CR3R4, OR3R4; R3R4 = (un)substituted alkylene, oxaalkylene, azaalkylene; at least one N atom is substituted by O] were prepared for use as antitumor agents (no data). Thus, I [R1 = H, R2 = Me, A = 4-methyl-4-oxido-1-piperazinyl] was prepared by oxidation of I [R1 = H, R2 = Me, A = 4-methyl-1-piperazinyl].
IT 571186-91-9P 571186-92-0P 571186-93-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoylaminophenylaminopyrimidinylpyridines as antitumor agents)
RN 571186-91-9 CAPLUS

CN Benzamide, 4-[(4-methyl-4-oxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 571186-92-0 CAPLUS
CN Benzamide, N-[4-methyl-3-[[4-(1-oxido-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (CA INDEX NAME)



RN 571186-93-1 CAPLUS
CN Benzamide, 4-[(4-methyl-1,4-dioxido-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    27.73      307.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -4.00       -4.00

STN INTERNATIONAL LOGOFF AT 21:27:41 ON 04 AUG 2008
```